CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) and Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.
Profitability
This table compares CRISPR Therapeutics and Ernexa Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CRISPR Therapeutics | -3,368.72% | -24.39% | -18.25% |
| Ernexa Therapeutics | N/A | -305.93% | -169.86% |
Risk and Volatility
CRISPR Therapeutics has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500. Comparatively, Ernexa Therapeutics has a beta of 2.63, indicating that its share price is 163% more volatile than the S&P 500.
Insider and Institutional Ownership
69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares CRISPR Therapeutics and Ernexa Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CRISPR Therapeutics | $3.51 million | 1,490.57 | -$581.60 million | ($4.76) | -11.37 |
| Ernexa Therapeutics | $580,000.00 | 5.57 | -$14.08 million | ($14.35) | -0.14 |
Ernexa Therapeutics has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for CRISPR Therapeutics and Ernexa Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CRISPR Therapeutics | 1 | 7 | 9 | 2 | 2.63 |
| Ernexa Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
CRISPR Therapeutics presently has a consensus price target of $65.75, suggesting a potential upside of 21.51%. Ernexa Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 1,415.15%. Given Ernexa Therapeutics’ higher possible upside, analysts plainly believe Ernexa Therapeutics is more favorable than CRISPR Therapeutics.
Summary
CRISPR Therapeutics beats Ernexa Therapeutics on 9 of the 15 factors compared between the two stocks.
About CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
About Ernexa Therapeutics
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
